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Robert M ConryAbstract
Follicular dendritic cell sarcoma is a rare malignancy arising from follicular dendritic cells, which form a meshwork
within lymphoid follicles. Traditional treatment of metastatic disease with CHOP chemotherapy, the most
commonly used regimen for lymphoid malignancies, has met with limited success. I report herein two cases of
follicular dendritic cell sarcoma metastatic to the liver treated with the combination of gemcitabine and docetaxel
showing unprecedented response in this disease. These observations coupled with recent evidence of a
mesenchymal origin of follicular dendritic cells support the premise that this malignancy should be treated similar
to other adult soft tissue sarcomas.
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Follicular dendritic cell sarcoma (FDCS) is a rare malig-
nancy arising from follicular dendritic cells which form
an arborizing meshwork within lymphoid follicles and
are involved in antigen capture, retention and presen-
tation to B cells. Follicular dendritic cells (FDCs) also
protect against autoimmunity by expediting removal of
potentially self-reactive debris from negatively selected,
apoptotic B lymphocytes in germinal centers [1]. The
hyaline vascular variant of Castleman’s disease, angiofol-
licular lymph node hyperplasia, involves a premalignant
proliferation of FDCs with dysplasia. Approximately 20%
of cases of FDCS are associated with this entity with se-
quential pathological changes from Castleman’s disease
to FDCS documented at individual sites in several repor-
ted cases [2,3]. Multicentric Castleman’s disease is usu-
ally responsive to CHOP chemotherapy or single agent
rituximab despite the fact that FDCs are CD20 negative.
The likely mechanism involves depletion of follicular B
lymphocytes with secondary reduction of lymphotoxin
and other mediator release essential for FDC develop-
ment. Evidence suggests that Epstein-Barr virus plays aCorrespondence: rconry@uabmc.edu
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and spleen [4].
FDCS affects males and females equally with a median
age at diagnosis of 47 years, with a wide range from 14
to 77 years [3]. Approximately 60% of cases arise in lymph
nodes, most commonly cervical or mediastinal. Some oc-
cur in extranodal sites including lung, liver, spleen and GI
tract [5]. FDCSs typically present as a large mass with
mean diameter ranging from 7 to 10 centimeters. Sys-
temic symptoms are uncommon. Pathologically, FDCSs
are well-circumscribed with spindle to ovoid cells ar-
ranged in a fascicular, whorled or storiform pattern, ty-
pically with infiltration by scattered small lymphocytes.
Ultrastructural examination reveals complex cytoplasmic
processes and features resembling fibroblasts [6]. Im-
munohistochemistry is required to make the diagnosis.
FDCSs are usually reactive for FDC markers CD21,
CD23, and CD35 [5]. Tumor cells also typically express
vimentin, a soft tissue sarcoma marker.
Surgical excision is the treatment of choice for loca-
lized FDCS with radiation therapy also used in approxi-
mately a third of cases. Local recurrences are reported in
30-40% of cases and metastases also develop in approxi-
mately 30% of patients. CHOP chemotherapy has been
the most frequently reported systemic therapy with tran-
sient, partial responses observed in some patients [7].is is an Open Access article distributed under the terms of the Creative
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of this regimen may derive primarily from doxorubicin,
one of the most broadly active agents against sarcoma in
general.
The regimen of gemcitabine and docetaxel is broadly
active against soft tissue sarcomas with relatively good
tolerability [8]. Gemcitabine 900 mg/m2 is administered
days 1 and 8 with docetaxel 100 mg/m2 administered
day 8 of a 21 day cycle with neulasta, G-CSF, given day
9. Response rates are improved using a fixed dose rate
infusion of gemcitabine at 10 mg per m2 per minute [9],
although cytopenias are somewhat more pronounced.
Although objective responses occur in 50% of leiomyo-
sarcomas, the overall response rate is approximately 20%
in previously treated soft tissue sarcomas in general [8].
A multicenter phase II trial compared gemcitabine with
or without docetaxel and the combination produced su-
perior objective response rate, progression-free survival
and overall survival [10]. Although RECIST responses
occured in only 16% of patients receiving the combin-
ation, median progression-free survival was 6.2 months
[10]. I report hereafter two cases of FDCS metastatic
to the liver with objective response to gemcitabine and
docetaxel.
Case report
Patient 1 was a 51-year-old Caucasian male who under-
went wide excision of a FDCS of the duodenal wall with
negative margins. This was a spindle cell malignancy
with immunohistochemistry positive for CD21, CD23 and
vimentin and negative for CD20, CD34, CD35, CD117
(c-kit), DOG 1 and smooth muscle actin. EGFR expression
was negative by immunohistochemistry and mutation
analysis was wild type. One year after surgery, he was di-
agnosed with multiple liver metastases confirmed by bi-
opsy and received six cycles of CHOP chemotherapy at
another medical center with partial response. However,
four months after completing CHOP he had marked
worsening of hepatic metastases with numerous lesions
affecting all hepatic segments up to 7 cm diameter. Prior
to transfer of care to our center, he went untreated for
two additional months during which time liver metastases
coalesced with the largest becoming 15 cm in diameter,
but the lungs remained clear. He had moderate right
upper quadrant pain and fullness, but surprisingly no con-
stitutional symptoms such as fatigue, anorexia or weight
loss. Due to limited tissue availability, only two genes were
sequenced to determine potential clinical trial eligibility,
and both BRAF and PI3KCA were wild type as has been
reported in FDCS. He received gemcitabine by fixed dose
rate infusion and docetaxel since he had already ap-
proached his lifetime limit of doxorubicin. After three
cycles, he achieved a RECIST 1.1 partial response with
the largest hepatic metastasis decreasing from 15 to9.5 cm diameter, the second largest decreasing from
10.3 to 7.0 cm and symptomatic improvement. After six
cycles, the hepatic metastases continued to respond
with the largest mass decreasing to 6.4 cm and the sec-
ond largest to 5.9 cm. Docetaxel was discontinued after
six cycles due to lower extremity edema and bilateral
pleural effusions, which subsequently resolved. Gemci-
tabine was continued for a total of 12 cycles with the
largest hepatic mass decreasing to 5 cm and the second
largest to 4.7 cm. Performance status and quality of
life remained excellent throughout treatment, and a
RECIST 1.1 partial response is continuing at the time
of this report.
Patient 2 was a 36-year-old African-American female
who presented with Coombs positive autoimmune hemo-
lytic anemia unresponsive to steroids successfully treated
with splenectomy. One year later, she developed gene-
ralized abdominal pain with a 9 cm left periaortic, me-
senteric mass with open biopsy revealing FDCS with brisk
mitoses (25 per 10 hpf). Immunohistochemistry was posi-
tive for CD21, CD23, EGFR, vimentin and dim CD35, but
negative for CD20, CD34, CD117 (c-kit) and DOG 1. In-
sufficient tissue was available for gene sequencing. Bone
marrow biopsy and aspirate were mildly hypercellular, but
otherwise unremarkable with normal karyotype. Her he-
moglobin was stably low at 10.5 with normal MCV and a
persistently positive direct Coombs test for IgG. Retros-
pectively, her autoimmune hemolysis requiring splenecto-
my appears likely related to subclinical FDCS, particularly
since FDCs are known to share antigens with erythrocytes,
including CD35. Over two months the primary tumor be-
came 30 percent larger and was treated with radiation. Six
months after completing radiation therapy, the primary
mass had decreased from 8.8 to 6.6 cm with increased cen-
tral necrosis, but multiple new hepatic metastases had de-
veloped up to 3.3 cm with lungs remaining clear. Liver
biopsy confirmed metastatic FDCS, and she received fixed
dose rate gemcitabine and docetaxel as initial systemic
therapy. After six cycles, she achieved a RECIST 1.1 partial
response with the largest liver metastasis decreasing from
3.3 cm to 1.8 cm and the second largest decreasing from
2.4 cm to 0.9 cm. After nine cycles of gemcitabine and do-
cetaxel, the largest metastasis further decreased to 1.5 cm
and the second largest remained stable at 0.9 cm. The radi-
ated periaortic primary gradually decreased in diameter
and developed calcifications. Chemotherapy was disconti-
nued after nine cycles due to plateauing response and fa-
tigue. At the time of this report, she has a continuing
RECIST 1.1 partial response two months after discon-
tinuing gemcitabine and docetaxel.
Discussion
The historic rationale for using CHOP chemotherapy,
the most commonly used regimen to treat intermediate
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volved several early observations linking FDCS with
B lymphocytes. For example, FDCSs most often arise
within lymph node follicles, 20% of cases occur within
a background of follicular lymph node hyperplasia, i.e.
Castleman’s disease, rare cases are associated with Epstein
Barr virus infection, and origin of FDCs from lymph-
oid precursors was postulated. However, response of
Castleman’s disease to CHOP likely involves depletion
of B lymphocytes with resultant reduction in para-
crine release of FDC growth factors rather than direct
cytotoxicity to FDCs. Furthermore, recent work has
shown FDC precursors to be of vascular stromal ra-
ther than lymphoid origin. FDCs can emerge anywhere
in the body during chronic inflammation and par-
ticipate in the organization of new B cell follicles in
non-lymphoid tissues suggesting the existence of a
ubiquitous progenitor. Recently discovered FDC pre-
cursors are sessile cells originating from vascular stroma
found throughout the body in vascular walls and ex-
pressing platelet-derived growth factor receptor beta [6].
Thus, FDCs are of mesenchymal origin [11]. FDCSs have
complex karyotypes associated with structural abnor-
malities and loss of multiple chromosomes as seen in
the majority of adult sarcomas [12], and the clinical
behavior of these tumors is more akin to that of low
to intermediate grade soft tissue sarcomas rather than
lymphoid malignancies.
This is the first report of objective response of this
rare sarcoma to combination chemotherapy with gemci-
tabine and docetaxel. These agents are generally well tol-
erated and applicable to patients across a broad range of
age and comorbidity. Response of FDCS to this com-
monly used sarcoma regimen further supports the mes-
enchymal nature of this malignancy and suggests a role
for other agents like pazopanib approved for soft tissue
sarcoma therapy.
Epidermal growth factor receptor (EGFR) expression
has been reported in normal FDCs, dysplastic FDCs as-
sociated with hyaline vascular Castleman’s disease and
16 of 16 cases of FDCS [11]. Yet, no EGFR mutations or
gene amplifications were observed. Absence of somatic
mutations of KRAS, NRAS, BRAF and PI3KCA in FDCS
suggests EGFR inhibition as another potential treatment
strategy [11].
Conclusion
Durable objective response to gemcitabine and docetaxel
was observed in two patients with follicular dendritic
cell sarcoma metastatic to the liver. This observation
supports the notion that FDCS should be treated similar
to other adult soft tissue sarcomas rather than lymphoid
malignancies. These are to my knowledge the only re-
ported cases of FDCS treated with the combination ofgemcitabine and docetaxel. This combination could rep-
resent a therapeutic alternative for follicular dendritic
cell sarcoma.
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